Musa Mayer of New York City was diagnosed with breast cancer 22 years ago. Since then, she has become a patient advocate and author of the highest integrity. She also continues to serve as a patient representative with several Food and Drug Administration (FDA) committees, with a vote on whether to approve new cancer drugs.
In this interview, Musa gives us an insider’s view into the way the FDA evaluates cancer drugs. Why does the approval of cancer drugs take so long? Why are some seemingly promising drugs not approved?
Musa also gives reasonable expectations for clinical trials and explains their role in the approval process. She gives us hope of how the linking between new cancer diagnostic tests and new drugs could accelerate the approval of medications.
View more programs featuring Musa Mayer
Become a member to access our latest content and be the first to know about new programs and information.